News Antengene Corporation Limited

Equities

6996

KYG039571008

Market Closed - Hong Kong S.E. Other stock markets 01:38:42 28/06/2024 pm IST			5-day change	1st Jan Change
0.78 ^HKD	-.--%		-4.88%	-61.00%

26/06	Antengene Announces XPOVIO® National Health Insurance Service Approval for Reimbursement in South Korea	CI
02/05	Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Antengene Announces XPOVIO National Health Insurance Service Approval for Reimbursement in South Korea	27/06	AQ
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea	26/06	PR
Antengene Announces XPOVIO® National Health Insurance Service Approval for Reimbursement in South Korea	26/06	CI
Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	02/05	MT
Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting	29/04	CI
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024	26/04	AQ
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline	25/03	AQ
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	20/03	CI
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms	07/03	AQ
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List	15/12	AQ
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List	14/12	MT
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List	14/12	PR
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	14/12	CI
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	11/12	AQ
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	11/12	CI
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma	07/12	AQ
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma	06/12	PR
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	06/12	CI
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	20/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Antengene Corporation Limited

Equities

6996

KYG039571008

Summary

Filters